Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2738)	3/24/2010 3:53:02 PM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

CBPO opened with a good UG, it was up 25.33% at its intraday H and still is up 22.58% at present. Volume of 476Ks is about 3.5x its ADV bigcharts.marketwatch.com It announced on Monday that it was going to host a C.C. at 9:00 a.m. today, to discuss the 4thQ quarter and full Yr. results. It released its earnings results prior to the CC.<g> The revenues on the 4thQ increased from 13.2M to 37.6M and earnings also on triple digit % from $0.15 to $0.44 For the Yr. earnings were $0.71 vs.$0.56 in 2008 and for 2010 a good increase in earnings is expected to around $1.20 <g> The Jan11 H was $13.70. It sems likely that the stock may pause or even close some of today's UG, but with the good EE, the ACTAY at $16 doesn't seems unreasonable.<g> bigcharts.marketwatch.com Bernard

To: Jibacoa who wrote (2738)	7/27/2010 2:42:24 PM
From: Jibacoa	Respond to of 3722

NVAX was up 7.14% and is still up 4.91% on volume still below its ADV. The stock opened with a small UG and is trading above its July Hs. It seems it wants to test the June 2 H at $2.43 The stock seems to have support at $2. <g> bigcharts.marketwatch.com NVAX announced today the issuance of U.S. Patent No. 7,763,450 for "Functional Influenza Virus-Like Particles". The patent covers the use of influenza gene sequences for high-yield production of consistent influenza VLP vaccines to protect against current and future seasonal and pandemic strains of influenza viruses. According to its Vicepresident, the VLP technology overcomes a major limitation of the current influenza virus vaccine technology that depends on strain selection and optimization every year. It enables a faster production of vaccine for the target influenza strain than the existing, egg-based process which resulted in significant delays in the manufacture of vaccines during the 2009 H1N1 pandemic emergency. The ACTAY is $6.38 I would keep a TT at $4<g> bigcharts.marketwatch.com Bernard